Eptifibatide

FDA Approved: * June 5, 2015
Pharm Company: * TEVA PHARMS USA
Category: Intravenous (IV) Therapy

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Eptifibatide Overview

Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.[1] Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inh...

Read more Eptifibatide Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Eptifibatide

Recent Eptifibatide Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Eptifibatide
  • Injection: 0.75mg/ml, 2mg/ml, 75mg/100ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Eptifibatide: (19 results)

Sorted by National Drug Code
  • 0703-1165 Eptifibatide 2 mg/ml Intravenous Injection, Solution by Teva Parenteral Medicines, Inc.
  • 0703-1179 Eptifibatide .75 mg/ml Intravenous Injection, Solution by Teva Parenteral Medicines, Inc.
  • 16729-259 Eptifibatide .75 mg/ml Intravenous Injection, Solution by Accord Healthcare Inc.
  • 16729-260 Eptifibatide 2 mg/ml Intravenous Injection, Solution by Accord Healthcare Inc.
  • 17478-902 Eptifibatide 2 mg/ml Intravenous Injection, Solution by Akorn, Inc.
  • 17478-903 Eptifibatide .75 mg/ml Intravenous Injection, Solution by Akorn, Inc.
  • 25021-408 Eptifibatide .75 mg/ml Intravenous Injection, Solution by Sagent Pharmaceuticals
  • 25021-409 Eptifibatide 2 mg/ml Intravenous Injection, Solution by Sagent Pharmaceuticals
  • 55150-218 Eptifibatide 75 mg/100ml Intravenous Injection by Auromedics Pharma LLC
  • 55150-219 Eptifibatide 20 mg/10ml Intravenous Injection by Auromedics Pharma LLC
  • 55150-220 Eptifibatide 200 mg/100ml Intravenous Injection by Auromedics Pharma LLC
  • 59651-012 Eptifibatide 75 mg/100ml Intravenous Injection by Aurobindo Pharma Limited
  • 59651-013 Eptifibatide 20 mg/10ml Intravenous Injection by Aurobindo Pharma Limited
  • 59651-014 Eptifibatide 200 mg/100ml Intravenous Injection by Aurobindo Pharma Limited
  • 67457-629 Eptifibatide 2 mg/ml Intravenous Injection, Solution by Mylan Institutional LLC
  • 67457-630 Eptifibatide 2 mg/ml Intravenous Injection, Solution by Mylan Institutional LLC
  • 67457-631 Eptifibatide .75 mg/ml Intravenous Injection, Solution by Mylan Institutional LLC
  • 70121-1002 Eptifibatide 2 mg/ml Intravenous Injection by Amneal Biosciences
  • 70121-1003 Eptifibatide .75 mg/ml Intravenous Injection by Amneal Biosciences

Other drugs which contain Eptifibatide or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 19 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA